首页> 美国卫生研究院文献>Annals of Oncology >PD-020Tolerability and activity of second-line tepotinib a potent and highly selective c-MET inhibitor in patients with advanced hepatocellular carcinoma previously treated with sorafenib

【2h】

PD-020Tolerability and activity of second-line tepotinib a potent and highly selective c-MET inhibitor in patients with advanced hepatocellular carcinoma previously treated with sorafenib

机译：PD-020二线tepotinib（一种有效且高度选择性的c-MET抑制剂）在先前接受索拉非尼治疗的晚期肝细胞癌患者中的耐受性和活性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 Annals of Oncology
作者
S. Faivre; J.-F. Blanc; P. Merle; A. Fasolo; A. Iacobellis; V. Grando; T. Decaens; J. Trojan; E. Villa; U. Stammberger; R. Bruns; E. Raymond;
展开▼
作者单位

展开▼
年(卷),期 -1(27),Suppl 2
年度 -1
页码 ii109
总页数 1
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment [J] . Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Investigational new drugs. . 2018,第2期

机译：索拉非尼治疗的先进肝细胞癌患者的特征有资格进行二线治疗
2. Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment [J] . Kuzuya Teiji, Ishigami Masatoshi, Ishizu Yoji, Oncology: International Journal of Cancer Research and Treatment . 2018,第2期

机译：索拉非尼患者治疗肝癌患者晚期肝细胞癌患者的预后存活率未讨论的第二线雷龙蒽苯胺治疗
3. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma [J] . A Santoro, T Pressiani, G Citterio, British Journal of Cancer . 2010,第6期

机译：选择性血管靶向剂NGR-hTNF在先前治疗的晚期肝细胞癌患者中的活性和安全性
4. Diffusion-weighted MR imaging of advanced hepatocellular carcinoma treated with the oral multikinase inhibitor Sorafenib [C] . C. Schraml, N.F. Schwenzer, H. Rempp, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：口服多激酶抑制剂索拉非尼治疗晚期肝癌的扩散加权MR成像
5. Activity and safety of NGR-hTNF a selective vascular-targeting agent in previously treated patients with advanced hepatocellular carcinoma [O] . A Santoro, T Pressiani, G Citterio, 2010

机译：选择性血管靶向剂NGR-hTNF在先前治疗的晚期肝细胞癌患者中的活性和安全性
6. Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib [O] . T. Decaens, C. Barone, E. Assenat, 2018

机译：患者（PTS）与先前用Sorafenib治疗的患者（PTS）患者（PTS）中的患者（PTS）中的疗效和安全性

PD-020Tolerability and activity of second-line tepotinib a potent and highly selective c-MET inhibitor in patients with advanced hepatocellular carcinoma previously treated with sorafenib

著录项

引文网络

相似文献

相关主题

期刊订阅